Clinical application of transcranial magnetic stimulation in multiple sclerosis

Zhou, Xiaoliang; Li, Kailin; Chen, Si; Zhou, Wenbin; Li, Jing; Huang, Qing; Xu, Tao; Wang, Dongyu; Zhao, Shengdun; Dong, Hui

doi:10.3389/fimmu.2022.902658

Cited by 8 publications

(4 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application of rTMS in the treatment of central nervous system diseases holds promise, but it is important to acknowledge its limitations. It is worth noting that rTMS can induce seizures when the frequency is high and the stimulation interval is short ( 70 ). The bidirectional regulation of human cortical excitability can be achieved by adjusting the stimulation rate ( 71 ).…”

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study

Yang,

Shangguan,

Wang

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

BackgroundThe new antiseizure medications (ASMs) and non-invasive brain stimulation (NIBS) are controversial in controlling seizures. So, this network meta-analysis aimed to evaluate the efficacy and safety of five third-generation ASMs and two NIBS therapies for the treatment of refractory epilepsy.MethodsWe searched PubMed, EMBASE, Cochrane Library and Web of Science databases. Brivaracetam (BRV), cenobamate (CNB), eslicarbazepine acetate (ESL), lacosamide (LCM), perampanel (PER), repetitive transcranial magnetic stimulation (rTMS), and transcranial direct current stimulation (tDCS) were selected as additional treatments for refractory epilepsy in randomized controlled studies and other cohort studies. Randomized, double-blind, placebo-controlled, add-on studies that evaluated the efficacy or safety of medication and non-invasive brain stimulation and included patients with seizures were uncontrolled by one or more concomitant ASMs were identified. A random effects model was used to incorporate possible heterogeneity. The primary outcome was the change in seizure frequency from baseline, and secondary outcomes included the proportion of patients with ≥50% reduction in seizure frequency, and the rate of treatment-emergent adverse events.ResultsForty-five studies were analyzed. The five ASMs and two NIBS decreased seizure frequency from baseline compared with placebo. The 50% responder rates of the five antiseizure drugs were significantly higher than that of placebo, and the ASMs were associated with fewer adverse events than placebo (p < 0.05). The surface under the cumulative ranking analysis revealed that ESL was most effective in decreasing the seizure frequency from baseline, whereas CNB provided the best 50% responder rate. BRV was the best tolerated. No significant publication bias was identified for each outcome index.ConclusionThe five third-generation ASMs were more effective in controlling seizures than placebo, among which CNB, ESL, and LCM were most effective, and BRV exhibited better safety. Although rTMS and tDCS did not reduce seizure frequency as effectively as the five drugs, their safety was confirmed.Systematic review registrationPROSPERO, https://www.crd.york.ac.uk/prospero/ (CRD42023441097).

show abstract

Section: Discussionmentioning

confidence: 99%

The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study

Yang,

Shangguan,

Wang

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Therefore, in 2008, the United States Food and Drug Administration approved the use of TMS in drug-resistant depression treatment ( 34 ). Currently, TMS is used in the treatment of nervous system diseases such as SCI ( 35 ), Alzheimer’s disease ( 36 ), Parkinson’s disease ( 37 ), multiple sclerosis ( 38 ), stroke-related disability ( 39 ), and schizophrenia ( 40 ). TMS use has achieved gratifying results in basic research and clinical trials; hence, it is a potential treatment method for nervous system diseases.…”

Section: Basic Principles and Classification Of Tmsmentioning

confidence: 99%

Research progress on the application of transcranial magnetic stimulation in spinal cord injury rehabilitation: a narrative review

Wang

Dong

et al. 2023

Front. Neurol.

View full text Add to dashboard Cite

Traumatic or non-traumatic spinal cord injury (SCI) can lead to severe disability and complications. The incidence of SCI is high, and the rehabilitation cycle is long, which increases the economic burden on patients and the health care system. However, there is no practical method of SCI treatment. Recently, transcranial magnetic stimulation (TMS), a non-invasive brain stimulation technique, has been shown to induce changes in plasticity in specific areas of the brain by regulating the activity of neurons in the stimulation site and its functionally connected networks. TMS is a new potential method for the rehabilitation of SCI and its complications. In addition, TMS can detect the activity of neural circuits in the central nervous system and supplement the physiological evaluation of SCI severity. This review describes the pathophysiology of SCI as well as the basic principles and classification of TMS. We mainly focused on the latest research progress of TMS in the physiological evaluation of SCI as well as the treatment of motor dysfunction, neuropathic pain, spasticity, neurogenic bladder, respiratory dysfunction, and other complications. This review provides new ideas and future directions for SCI assessment and treatment.

show abstract

“…Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment approved by the US Food and Drug Administration (FDA) and the National Institute for Health and Care Excellence (NICE) in the UK [1,2]. RTMS has been tested with modest success in movement disorders such as dystonia, tremors [3], and multiple sclerosis and is often used for neurological rehabilitation [4]. In psychiatry, rTMS has shown e cacy in treating various anxiety disorders such as panic disorder and obsessive-compulsive disorder (OCD), as well as auditory hallucinations, negative symptoms of schizophrenia, and major depressive disorder (5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Awareness of transcranial magnetic stimulation among psychiatrists in Oman towards transcranial magnetic stimulation: Single institution study

Al-Balushi,

AL-Huseini,

Chan

et al. 2024

Preprint

View full text Add to dashboard Cite

Background: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive treatment method that is increasingly becoming prominent due to the limitations of existing pharmacopsychotherapy modalities. To date, a dearth of studies examines the awareness of rTMS among psychiatrists in the Arabian Gulf population. In this region, resistance to treatment is widespread due to the cultural attribution of ‘psychic pain’ to somatic attribution and the stigma associated with pharmaco-psychotherapy. Aims: This study aimed to assess the understanding and attitudes of psychiatrists towards rTMS and determine the factors that contribute to the knowledge of rTMS in Oman. Methods: A quantitative observational cross-sectional study will be conducted using an online survey. The survey will collect demographic information, and a validated measure was adopted to assess variation in knowledge and attitudes towards rTMS was adopted. Univariate analysis and multiple linear regression will be performed to identify risk factors associated with knowledge levels. Result: 50 psychiatrists participated in this study, resulting in a response rate of 83%. The average age of the participants was 32.7±4.3 years [26.0-41.0], with more than half being female (n=28, 56.0%) and residents (Junior/Senior) (n=25, 50.0%). Most of the sample were Omani (n=45, 90.0%) and worked in tertiary hospitals (n=38, 76.0%). The average scores for knowledge and attitudes towards rTMS in this sample were 14.5±3.8 and 22.5±6.3, respectively. The linear model showed that seniors and older had a higher level of knowledge than junior residents (ß=4.65, p<.001). Furthermore, participants who had access to an rTMS device at work had a higher level of knowledge than those who did not (ß=1.88, p=0.027). Conclusion: Three factors significantly impact the knowledge of psychiatrists about rTMS: their higher educational level, the presence of an rTMS device at work, and the availability of standardized training in rTMS.

show abstract

Clinical application of transcranial magnetic stimulation in multiple sclerosis

Cited by 8 publications

References 75 publications

The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study

The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study

Research progress on the application of transcranial magnetic stimulation in spinal cord injury rehabilitation: a narrative review

Awareness of transcranial magnetic stimulation among psychiatrists in Oman towards transcranial magnetic stimulation: Single institution study

Contact Info

Product

Resources

About